ATNM

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $25.00. The company's shares closed last Tuesday at $6.53. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -29.4% and a 15.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Monopar Therapeutics Inc. Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $35.00, implying a 431.1% upside from current levels.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-receives-a-buy-from-maxim-group?utm_source=advfn.com&utm_medium=referral